EMEA-002900-PIP01-20-M02 - paediatric investigation plan

tixagevimab
PIPHuman

Key facts

Invented name
Evusheld
Active Substance
tixagevimab
Therapeutic area
Infections and infestations
Decision number
P/0459/2023
PIP number
EMEA-002900-PIP01-20-M02
Pharmaceutical form(s)
Solution for injection/infusion
Condition(s) / indication(s)
  • Prevention or treatment of COVID-19
  • Treatment of Coronavirus disease 2019 (COVID-19)
Route(s) of administration
  • Intramuscular use
  • Intravenous use
Contact for public enquiries

AstraZeneca AB

E-mail: paediatrics@astrazeneca.com

Tel. +46 8553 27591

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

Share this page